Purdue Pharma L.P. (“Purdue”) announced today that the company
has partnered with MMCAP Infuse to provide buprenorphine and
naloxone tablets CIII (generic Suboxone®), a medication for opioid
use disorder (“MOUD”), at low cost to correctional facilities for
incarcerated individuals with opioid use disorder. MMCAP Infuse is
a national cooperative group purchasing organization operated by
the State of Minnesota, Office of State Procurement, for government
facilities that provide healthcare services. Under the agreement,
to increase access to treatment for incarcerated individuals,
Purdue will provide for distribution approximately 1.25 million
tablets at the cost of one penny ($0.01) per tablet.
The Office of National Drug Control Policy (“ONDCP”) reports
that substance use disorder affects an estimated 65 percent of
incarcerated individuals, 1 and correctional facilities often face
cost barriers in providing adequate substance use disorder
treatment.2 Moreover, according to ONDCP, research shows that
individuals leaving prison face a “meaningful elevated risk” of
opioid overdose death [up to 40 times higher] than that of the
general population during the first two weeks following their
release.1,3 However, research also indicates that treatment with
MOUDs during incarceration can reduce the risk of drug overdose
death in the first month post release by 85 percent.1
“Our agreement with MMCAP Infuse supports the objectives
identified by ONDCP and other government agencies that have
emphasized the need to expand access to MOUD for incarcerated
individuals,” said Craig Landau, MD, President and CEO of Purdue.
“Unfortunately, too many in this patient population are left in
need of treatment. We are committed to delivering solutions to help
with this complex crisis and working with partners such as MMCAP
Infuse to bring medication to those who need it most.”
This buprenorphine/naloxone tablet distribution effort is an
important part of Purdue’s Public Health Initiatives, which focus
on the development and distribution of medicines that reverse
opioid overdoses and treat opioid use disorder. Rhodes
Pharmaceuticals, a wholly owned subsidiary of Purdue, distributes
this medication.
Buprenorphine and Naloxone Sublingual Tablets CIII
INDICATIONS AND USAGE
Buprenorphine and naloxone sublingual tablets are indicated for
maintenance treatment of opioid dependence. Buprenorphine and
naloxone sublingual tablets should be used as part of a complete
treatment plan that includes counseling and psychosocial
support.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Buprenorphine and naloxone sublingual tablet is contraindicated
in patients with a history of hypersensitivity to buprenorphine or
naloxone as serious adverse reactions, including anaphylactic
shock, have been reported.
WARNINGS AND PRECAUTIONS
Addiction, Abuse, and
Misuse
Buprenorphine and naloxone sublingual tablets contain
buprenorphine which can be abused in a manner similar to other
opioids. Monitor patients for conditions indicative of diversion or
progression of opioid dependence and addictive behaviors. Multiple
refills should not be prescribed early in treatment or without
appropriate patient follow-up visits.
Risk of Life-threatening Respiratory
Depression and Central Nervous System (CNS)
Depression
Buprenorphine has been associated with life-threatening
respiratory depression and death. Warn patients of the potential
danger of self-administration of benzodiazepines or other CNS
depressants, including alcohol, while under treatment with
buprenorphine and naloxone sublingual tablets. Use with caution in
patients with compromised respiratory function (e.g., chronic
obstructive pulmonary disease, cor pulmonale, decreased respiratory
reserve, hypoxia, hypercapnia, or pre-existing respiratory
depression). Opioids can cause sleep-related breathing disorders
including central sleep apnea (CSA), sleep-related hypoxemia.
Patient Access to Naloxone for the
Emergency Treatment of Opioid Overdose
Strongly consider prescribing naloxone for the emergency
treatment of opioid overdose, both when initiating and renewing
treatment with buprenorphine and naloxone sublingual tablets and
consider prescribing naloxone if the patient has household members
(including children) or other close contacts at risk for accidental
ingestion or opioid overdose.
Advise patients and caregivers that naloxone may also be
administered for a known or suspected overdose with buprenorphine
and naloxone sublingual tablet itself. Educate patients and
caregivers on how to recognize respiratory depression and, if
naloxone is prescribed, how to treat with naloxone. Emphasize the
importance of calling 911 or getting emergency medical help, even
if naloxone is administered.
Managing Risks from Concomitant Use of
Benzodiazepine or Other CNS Depressants
Concomitant use of buprenorphine and benzodiazepines or other
CNS depressants increases the risk of adverse reactions including
overdose and death. Medication-assisted treatment of opioid use
disorder, however, should not be categorically denied to patients
taking these drugs. Prohibiting or creating barriers to treatment
can pose an even greater risk of morbidity and mortality due to the
opioid use disorder alone. As a routine part of orientation to
buprenorphine treatment, educate patients about the risks of
concomitant use of benzodiazepines, sedatives, opioid analgesics,
and alcohol.
Unintentional Pediatric
Exposure
Buprenorphine can cause severe, possibly fatal, respiratory
depression in children. Store buprenorphine and naloxone
sublingual tablet safely out of the sight and reach of
children.
Neonatal Opioid Withdrawal
Syndrome
Neonatal opioid withdrawal syndrome (NOWS) is an expected and
treatable outcome of prolonged use of opioids during pregnancy.
Advise pregnant women receiving opioid addiction treatment with
buprenorphine and naloxone sublingual tablets of the risk of
neonatal opioid withdrawal syndrome.
Adrenal Insufficiency
If diagnosed with adrenal insufficiency treat with physiologic
replacement of corticosteroids, and wean patient off of the opioid.
Risk of Opioid Withdrawal with Abrupt
Discontinuation
If treatment is temporarily interrupted or discontinued, monitor
patients for withdrawal and treat appropriately.
Risk of Hepatitis, Hepatic
Events
Monitor liver function tests prior to initiation and during
treatment and evaluate suspected hepatic events.
Hypersensitivity
Reactions
Cases of bronchospasm, angioneurotic edema, and anaphylactic
shock have been reported. The most common signs and symptoms
include rashes, hives, and pruritus.
Precipitation of Opioid Withdrawal
Signs and Symptoms
An opioid withdrawal syndrome is likely to occur with parenteral
misuse of buprenorphine and naloxone sublingual tablet by
individuals physically dependent on full opioid agonists, or by
sublingual administration before the agonist effects of other
opioids have subsided.
Risk of Overdose in Opioid-Naïve
Patients
Buprenorphine and naloxone sublingual tablet is not appropriate
as an analgesic. There have been reported deaths of opioid naïve
individuals who received a 2 mg sublingual dose.
Use in Patients with Impaired Hepatic
Function
Buprenorphine/naloxone products are not recommended in patients
with severe hepatic impairment and may not be appropriate for
patients with moderate hepatic impairment. Use of
buprenorphine/naloxone may result in an increased risk of
precipitated withdrawal at the beginning of treatment (induction)
and may interfere with buprenorphine's efficacy throughout
treatment.
Dental Adverse Events
Cases of dental caries, some severe (i.e., tooth fracture, tooth
loss), have been reported following the use of transmucosal
buprenorphine-containing products. Educate patients to seek dental
care and strategies to maintain or improve oral health while being
treated with buprenorphine and naloxone sublingual tablets.
QTc Prolongation
Thorough QT studies with buprenorphine products have
demonstrated QT prolongation ≤15 msec. The risk of combining
buprenorphine with other QT prolonging agents is not known.
Consider these observations in clinical decisions when prescribing
buprenorphine and naloxone sublingual tablets to patients with
QT-related risk factors.
Impairment of Ability to Drive or
Operate Machinery
Caution patients that buprenorphine and naloxone sublingual
tablets may impair the mental or physical abilities required for
the performance of potentially dangerous tasks such as driving a
car or operating machinery.
Orthostatic Hypotension
Like other opioids, buprenorphine and naloxone sublingual
tablets may produce orthostatic hypotension in ambulatory
patients.
Elevation of Cerebrospinal Fluid
Pressure
Buprenorphine, like other opioids, may elevate cerebrospinal
fluid pressure and should be used with caution in patients with
head injury, intracranial lesions, and other circumstances when
cerebrospinal pressure may be increased. Buprenorphine can produce
miosis and changes in the level of consciousness that may interfere
with patient evaluation.
Elevation of Intracholedochal
Pressure
Buprenorphine has been shown to increase intracholedochal
pressure, as do other opioids, and thus should be administered with
caution to patients with dysfunction of the biliary tract.
Effects in Acute Abdominal
Conditions
As with other opioids, buprenorphine may obscure the diagnosis
or clinical course of patients with acute abdominal conditions.
ADVERSE REACTIONS
Adverse events commonly observed with buprenorphine and naloxone
sublingual tablets include oral hypoesthesia, glossodynia, oral
mucosal erythema, headache, nausea, vomiting, hyperhidrosis,
constipation, signs and symptoms of withdrawal, insomnia, pain, and
peripheral edema.
DRUG INTERACTIONS
Benzodiazepines or other Central
Nervous System (CNS) Depressants: Use with caution in patients receiving
benzodiazepines or other CNS depressants and warn patients against
concomitant self-administration and misuse.
CYP3A4 Inhibitors and
Inducers: Monitor patients
starting or ending CYP3A4 inhibitors or inducers for potential
over- or under- dosing.
Antiretrovirals: Patients
who are on chronic buprenorphine treatment should have their dose
monitored if NNRTIs are added to their treatment regimen. Monitor
patients taking buprenorphine and atazanavir with and without
ritonavir, and reduce dose of buprenorphine if warranted.
Serotonergic Drugs:
Concomitant use may result in serotonin syndrome. Discontinue
buprenorphine and naloxone sublingual tablets if serotonin syndrome
is suspected.
USE IN SPECIFIC POPULATIONS
Lactation: Buprenorphine
passes into the mother’s milk. Advise breastfeeding women to
monitor the infant for increased drowsiness and breathing
difficulties.
Geriatric patients: Monitor
geriatric patients for sedation and respiratory depression.
Moderate and Severe Hepatic
Impairment: Buprenorphine/naloxone products are not
recommended in patients with severe hepatic impairment and may not
be appropriate for patients with moderate hepatic impairment.
Please read Full Prescribing
Information.
To report SUSPECTED ADVERSE REACTIONS, contact Purdue Pharma
L.P. at 1-888 726-7535, option 2, or FDA at 1-800-FDA-1088 or
www.fda.gov/safety/medwatch.
Intended for healthcare professionals of the United States of
America only.
About Purdue Pharma L.P.
Purdue Pharma and its subsidiaries develop, manufacture and
market medications to meet the evolving needs of healthcare
professionals, patients, and caregivers. Purdue’s plan of
reorganization will deliver billions in value to communities across
the country to fund programs specifically for abatement of the
opioid crisis. The bankruptcy settlement will also deliver funds to
private abatement trusts for the benefit of personal injury
claimants.
Substantially all of Purdue’s assets will be transferred to a
new post-emergence company with a public-minded mission. This new
company will be governed by new independent board members and will
operate in a responsible and sustainable manner taking into account
long-term public health interests relating to the opioid crisis.
The company will continue serving patients who rely on its
medicines, pursuing its pipeline and introducing medicines that
will help save and improve lives.
For more information, visit www.purduepharma.com.
References:
- The White House, Executive Office of the President, Office of
National Drug Control Policy (ONDCP). National Drug Control
Strategy.
https://www.whitehouse.gov/wp-content/uploads/2022/04/National-Drug-Control-2022Strategy.pdf
- Ryan DA, Montoya ID, Koutoujian PJ, et al. Budget impact tool
for the incorporation of medications for opioid use disorder into
jail/prison facilities. Journal of Substance Use and Addiction
Treatment. 2023;146, 208943.
https://doi.org/10.1016/j.josat.2022.208943
- Ranapurwala SI, Shanahan ME, Alexandridis AA, et al. Opioid
overdose mortality among former North Carolina inmates: 2000-2015.
Am J Public Health. 2018;108(9):1207-1213. doi:
10.2105/AJPH.2018.304514.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506454441/en/
Media Contact: news@pharma.com